Cingulate Inc. Profile Avatar - Palmy Investing

Cingulate Inc.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is …

Biotechnology
US, Kansas City [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group

Peers Performance

A quick analysis that compared Cingulate Inc. (CING) to it's peer group.

Peer Group
Loading...
End of CING's Analysis
CIK: 1862150 CUSIP: 17248W105 ISIN: US17248W2044 LEI: - UEI: -
Secondary Listings
CING has no secondary listings inside our databases.